MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Checkpoint Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

4.03 -0.25

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.98

Max

4.04

Schlüsselkennzahlen

By Trading Economics

Angestellte

23

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+31.19% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

9. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

207M

Vorheriger Eröffnungskurs

4.28

Vorheriger Schlusskurs

4.03

Nachrichtenstimmung

By Acuity

50%

50%

166 / 386 Ranking in Healthcare

Checkpoint Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. März 2025, 10:23 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma

14. Dez. 2024, 00:24 UTC

Wichtige Markttreiber

Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval

25. Juli 2024, 13:02 UTC

Wichtige Markttreiber

Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab

10. März 2025, 02:12 UTC

Akquisitionen, Fusionen, Übernahmen

Checkpoint Controlling Shareholder Fortress Has Agreed to Vote in Favor of Transaction >524715.BY

10. März 2025, 02:12 UTC

Akquisitionen, Fusionen, Übernahmen

Sun Pharma, Checkpoint Transaction Expected to Complete in 2Q 2025 >524715.BY

10. März 2025, 02:11 UTC

Akquisitionen, Fusionen, Übernahmen

Sun Pharma, Checkpoint, Fortress Biotech Enter Into Royalty Agreement >524715.BY

10. März 2025, 02:11 UTC

Akquisitionen, Fusionen, Übernahmen

Checkpoint Shareholders Entitled to Receive Up to Additional $0.70 if Cosibelimab if Approved in EU Prior to Certain Deadlines >524715.BY

10. März 2025, 02:10 UTC

Akquisitionen, Fusionen, Übernahmen

Checkpoint Shareholders to Receive Upfront Cash Payment of $4.10/Share, Contingent Value Right >524715.BY

10. März 2025, 02:10 UTC

Akquisitionen, Fusionen, Übernahmen

Sun Pharma to Acquire Checkpoint Therapeutics >524715.BY CKPT

10. März 2025, 02:06 UTC

Akquisitionen, Fusionen, Übernahmen

Sun Pharma To Acquire Checkpoint Therapeutics >524715.BY CKPT

Peer-Vergleich

Kursveränderung

Checkpoint Therapeutics Inc Prognose

Kursziel

By TipRanks

31.19% Vorteil

12-Monats-Prognose

Durchschnitt 5.3 USD  31.19%

Hoch 7 USD

Tief 4.1 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Checkpoint Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

1

Buy

2

Halten

0

Sell

Stimmung

By Acuity

166 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

$

Über Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.